Canada markets closed

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5701-0.0126 (-2.16%)
At close: 04:00PM EDT
0.6400 +0.07 (+12.26%)
After hours: 06:38PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    Acasti Announces Court Dismissal of Stockholder Litigation

    LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today that a U.S. court has dismissed the remaining stockholder litigation filed in connection with the Company’s acquisition of Grace Therapeutics, Inc. (“Grace”) via merger in August 2021 (the “Merger”). As previously disclosed, four st

  • GlobeNewswire

    Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

    LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) which was held virtually on Wednesday September 28, 2022. Election of Directors All five (5) nominees listed in the proxy statement dated

  • Newsfile

    Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

    Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on a recent press release detailing the Company's clinical study for its GTX-102 asset, an oral mucosal spray targeting Ataxia-telang